Full history for every metric is available with a Kvantra account
ReNeuron Group plc (RENE.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 6 | 0 | 0 | 1 | 0 |
| Operating profit | £m | -7 | -6 | |||||
| Net profit | £m | -18 | -14 | -11 | -11 | -10 | -5 | -5 |
| EPS reported | £ | -0.09 | -0.09 | |||||
| Operating cashflow per share | £ | -0.13 | -0.13 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.13 | -0.13 | |||||
| Free cash flow | £m | -8 | -5 | |||||
| Net debt | £m | -7 | -5 | |||||
| Book value equity | £m | 5 | 2 | |||||
| Book value per share | £ | 0.09 | 0.04 | |||||
| Number of shares | m | 57.13 | 57.17 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.01 | 0.80 | |||||
| P/S LTM | x | 0.10 | 7.75 | |||||
| P/FCF LTM | x | -0.01 | -0.36 | |||||
| EV/EBITDA LTM | x | 0.89 | 0.53 | |||||
| EV/Sales LTM | x | -10.72 | -12.63 | |||||
| Earnings Yield LTM | % | -10460.6% | -11395.0% | |||||
| FCF Yield | % | -14901.6% | -276.01% | |||||
| Quality | ||||||||
| ROE | % | -106.94% | -72.37% | |||||
| ROIC | % | -105.51% | -105.51% | |||||
| Operating margin | % | -1342.5% | -1342.5% | |||||
| Gross margin | % | 49.62% | -742.08% | |||||
| FCF/Sales | % | -1453.6% | -1453.6% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +31.51% | -68.20% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -18.30 | -15.44 | |||||
| Net Debt/EBITDA | x | 0.90 | 0.90 | |||||
| EBIT/Net interest | x | -355.75 | -355.75 | |||||
| Net debt/market cap | % | -13835.9% | -263.01% | |||||
| Net debt/Equity | x | -1.41 | -2.10 | |||||
| Gross debt/equity | x | 0.08 | 0.14 | |||||
Company overview
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ReNeuron Group plc (RENE.L)
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free